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Abstract
Background: This post hoc subanalysis examined outcomes in adult patients with Morquio A
(mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks
period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfase alfa (modified
per protocol [MPP], n = 32; intent-to-treat [ITT], n = 37; MOR-005; NCT01415427) were compared with the ≥18-year-old
untreated population with 2-years follow-up from a Morquio A natural history study (n = 10; MorCAP; NCT00787995).
The MOR-005 MPP population excluded patients who underwent orthopedic surgical procedures or were
noncompliant with study protocol (defined as missing ≥20% of ERT infusions). No MorCAP patients underwent
orthopedic surgical procedures during the relevant time period. Endurance was assessed by the 6-min walk test
(6MWT) and 3-min stair climb test (3MSCT). Activities of daily living (ADLs) were assessed by the MPS Health
Assessment Questionnaire (MPS HAQ).
Results: Least squares (LS) mean (SE) 6MWT distances increased by 34.9 (11.7) m (MPP) and 30.5 (10.8) m (ITT) by
week 120; LS mean (SE) change in 3MSCT at week 120 was 6.7 (1.8) stairs/min (MPP) and 5.9 (1.7) stairs/min (ITT).
MorCAP patients showed no improvement in 6MWT distance or 3MSCT over a similar period of time. Pulmonary
function measures remained unchanged in both MOR-005 and MorCAP adults. All MPS HAQ domain scores improved
in MOR-005 adults, whereas MorCAP adults had unchanged caregiver assistance and mobility outcomes and worsened
self-care outcomes.
Conclusions: Long-term ERT in adult patients with Morquio A was associated with increased endurance and
improvement in performance of ADLs.
Trial registration: Trial Registration NCT01415427. Name of registry: Long-Term Efficacy and Safety Extension Study of
BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). Registered 8 August 2011, retrospectively
registered.
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Background
Morquio A syndrome (mucopolysaccharidosis IVA
[MPS IVA]; OMIM #253000) is an autosomal recessive
lysosomal storage disorder caused by deficiency in the
enzyme N-acetylgalactosamine-6-sulfatase (GALNS; EC
3.1.6.4), resulting in impaired degradation of the glycos-
aminoglycans (GAGs) keratan sulfate (KS) and
chondroitin-6-sulfate. Accumulation of these GAGs [1]
leads to progressive development of clinical features, in-
cluding skeletal and joint abnormalities, short stature,
cardiorespiratory compromise, impaired vision, hearing
loss, and hepatomegaly [2–4]. Estimates of the birth
prevalence of this rare genetic disorder range from 1 per
76,000 to 1 per 1,179,000 [5].
The natural history of untreated Morquio A is a progres-
sive worsening of symptoms with age [3, 6], along with de-
clines in mobility, activities of daily living (ADLs),
independence, and health related quality of life (HRQOL),
as well as declining respiratory function and excessive fa-
tigue [3, 7]. Patients with Morquio A have diminished life
spans [8]. Most patients with the classical Morquio A
phenotype generally die in the second to third decade of life
if untreated, primarily related to cervical instability and pul-
monary compromise. Approximately 25% of patients may
have an attenuated, slowly progressing phenotype, with
some patients reported to survive into the seventh decade
of life [9].
Elosulfase alfa (Vimizim®; BioMarin Pharmaceutical
Inc, Novato, CA, USA) is a recombinant human GALNS
that has been recently approved as enzyme replacement
therapy (ERT) for Morquio A [10]. Considering the irre-
versible damage caused by Morquio A, International
management guidelines recommend that elosulfase alfa
treatment be implemented as soon as the diagnosis of
Morquio A has been confirmed [11].
The safety and efficacy of elosulfase alfa have been inves-
tigated in more than 200 patients from both randomized
clinical trials and open-label extensions. In the pivotal
phase III, 24-weeks, randomized, placebo-controlled study
(MOR-004; NCT01275066), weekly infusions of elosulfase
alfa 2.0 mg/kg significantly improved performance in the
primary efficacy measure, the 6-min walk test (6MWT)
distance. The long-term benefit of elosulfase alfa treatment
has been demonstrated in an open-label extension trial
(MOR-005; NCT01415427), in which patients from MOR-
004 were enrolled for an additional 96 weeks (for a total of
120 weeks). At the end of 120 weeks, improvement in the
6MWT distance was observed in the overall population (all
of whom had advanced to the 2-mg/kg/week dose by that
time), as well as in the subset who received 2 mg/kg/week
for the entire 120 weeks [12].
The elosulfase alfa study populations were composed
largely of pediatric patients, likely due to the early mortality
caused by the disease. More than 75% of the patients in
MOR-004 were ≤18 years of age [13], with similar ages in
MOR-005. Considering the documented importance of
early treatment in MPS disorders [14–19], the benefits of
initiating ERT in adults with symptoms that have already
progressed is a clinically relevant issue that has not been
adequately investigated. This study was a post hoc analysis
of the adult population who participated in the MOR-005
extension study and specifically explored long-term clinical
and patient-reported outcomes over 120 weeks in adults
with Morquio A.
Methods
Study design
This international, multicenter, open-label trial was an ex-
tension of a randomized, double-blind, placebo-controlled,
24-weeks, phase III clinical study and was designed to evalu-
ate the long-term efficacy and safety of elosulfase alfa treat-
ment in patients with Morquio A (n = 173) [11, 13]. Details
of the study design have been previously reported [12].
MOR-005 consisted of two parts. In part 1, patients assigned
to 2 mg/kg/week (QW-QW cohort) and 2.0 mg/kg/every
other week (QOW-QOW cohort) in MOR-004 remained
on their regimen, whereas those assigned to placebo were
randomized 1:1 to one of the two dosing regimens. In part
2, all patients were switched to 2.0 mg/kg/week. (Study de-
sign presented in Additional file 1: Figure S1.)
Patient selection
Selection criteria for MOR-005 have been previously re-
ported [12]. This report was a post hoc subanalysis of
the adult patients (≥18 years of age) who participated in
MOR-005.
Efficacy evaluation
The primary efficacy measure was distance (m) walked in
the 6MWT, which evaluates functional exercise capacity
and endurance. Secondary endpoints included the 3-min
stair climb test (3MSCT), also a measure of endurance, and
urinary KS (uKS) levels normalized to urine creatinine. Re-
spiratory function was assessed by forced vital capacity,
forced expiratory volume in 1 s, and maximal voluntary
ventilation tests in accordance with the American Thoracic
Society guidelines [20]. The Health Assessment Question-
naire adapted for patients with MPS (MPS HAQ) [3]
assessed ADLs and extent of disability in the domains of
self-care, mobility, and amount of caregiver assistance
required. Higher numbers on the HAQ domain scores
indicate greater impairment. The individual items on the
self-care and mobility domains were rated from 0 (not
difficult at all) to 11 (unable to do) and averaged to provide
a domain score also ranging from 0 to 11. The items on the
caregiver assistance domain were rated from 1 to 4 and
were summed together to provide a score ranging
from 13 to 52.
Hughes et al. Orphanet Journal of Rare Diseases  (2017) 12:98 Page 2 of 8
The placebo group from MOR-004 was transitioned to
QW or QOW dosing after the 24-weeks double-blind
phase, and therefore no placebo group was included in
MOR-005. However, to provide context for interpret-
ation of the results, data from untreated patients were
obtained from the Morquio A Clinical Assessment Pro-
gram (MorCAP) natural history study (MOR-001;
NCT00787995). MorCAP was an international, multi-
center, cross-sectional study, subsequently amended as a
longitudinal study [3, 7]. The comparison group for this
report consisted of individuals who were ≥18 years of
age at baseline, had a mean 6MWT distance ≥30 m to
≤325 m, and had 2-years follow-up data.
Safety evaluation
A detailed description of safety assessments performed
during MOR-005 has been previously reported and in-
cluded adverse events (AEs), vital signs, concomitant
medications, infusion-associated reactions, clinical la-
boratory results, physical exam results, and immunogen-
icity testing results [12].
Statistical methods
In addition to the intent-to-treat (ITT) population in
MOR-005, a modified per-protocol (MPP) population
analysis was performed to address the impact of ortho-
pedic surgical procedures and noncompliance with study
protocol. Because orthopedic surgical procedures and
the subsequent recovery period can affect mobility and
endurance tests, both positively and negatively, patients
who underwent orthopedic operations during the study
were excluded from the MPP analysis. Patients were also
excluded from the MPP population for noncompliance,
defined as missing ≥20% of scheduled elosulfase alfa in-
fusions during MOR-005. Descriptive statistics of the ef-
ficacy endpoints are provided for the ITT and MPP
populations, both pooled and by treatment cohort (Add-
itional files 2 and 3: Tables S1 and S2). Comparison of
least squares (LS) mean efficacy assessments between
week 120 and baseline used a repeated-measures analysis
of covariance model. For the 6MWT, the model included
baseline 6MWT category (< or ≥200 m), treatment, time
point, and treatment and time point interaction. For
3MSCT and uKS level, the models also included baseline
measurement for 3MSCT and uKS level, respectively.
For all other assessments, baseline measurement for the
respective assessment replaced baseline 6MWT category.
The same models were used to compare year 2 and
baseline for the respective assessments in the MorCAP
population. The safety analysis included patients who
received any dose of study drug and had any posttreat-
ment safety assessments (ITT population). The inci-
dence of AEs was summarized by severity and relation
to study drug.
Results
Patient characteristics
The patient characteristics for the overall population in
MOR-005 have been published previously [12]. Of the
39 patients ≥18 years of age in the MOR-004 ITT popu-
lation, one discontinued early in the study (day 16) for
personal reasons. Thirty-eight patients completed MOR-
004 and 37 continued into MOR-005; 32 of these pa-
tients were included in the MPP population for both
studies. During MOR-005, one patient discontinued due
to safety and compliance issues (ITT population only)
and four discontinued due to study termination by the
sponsor (both ITT and MPP populations).
To serve as a comparator, patients were selected from
the MorCAP study of the natural history of untreated
Morquio A syndrome [7]. Of the 353 patients in MorCAP,
10 were ≥18 years of age, with 2-years follow-up data, and
met the inclusion criteria for MOR-004/005. The number
of patients with data available at each assessment ranged
from 4 to 10. No patients from this MorCAP subpopula-
tion underwent orthopedic operations during the relevant
time period. Therefore, data from the same group of pa-
tients were used for comparison with the MOR-005 ITT
and MPP populations.
Due to the observational nature of the natural history
study, the exact interval of follow-up visits varied between
638 and 939 days (91–134 weeks) for the year 2 assessment.
The mean (SD) actual visit time was 773 (102) days, or ap-
proximately 110 weeks. Table 1 shows the demographics
and baseline characteristics for the adults enrolled in
MOR-005, as well as the corresponding subpopulation
from the MorCAP study. Adult patients in MOR-004/005
had mean baseline height, endurance, and pulmonary func-
tion measures that were higher than those in MorCAP,
whereas the MorCAP patients were younger than the
MOR-004/005 patients; baseline MPS-HAQ scores were
similar between groups. Although their baseline mean
height (114.1 cm, ITT) is characteristic of a severely af-
fected group, the adult patients in MOR-004/005 were still
taller than the MOR-004 overall population (mean baseline
range, 101–105 cm), indicating that the disease in these
adults was slightly attenuated, as is consistent with their
prolonged survival [13].
Primary efficacy measure
For adult patients in MOR-005, the LS mean (SE)
increase from MOR-004 baseline to week 120 in
the 6MWT was 30.5 (10.8) m for the ITT population
(P = .0064) and 34.9 (11.7) m for the MPP group
(P = .0042) (Fig. 1a; Additional file 4: Table S3). In
comparison, the MorCAP patients (n = 10) did not
show improvement over 2 years, with an LS mean
change of 6.5 m, well within the SE of 15.9 m. Of the
ITT population, a subset of 10 patients (34.4%)
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received the approved 2-mg/kg QW dose in both
MOR-004 and MOR-005 for a total of 120 weeks.
The mean (SE) change in the 6MWT distance at
week 120 for this cohort receiving the more effica-
cious dose throughout the study was 54.4 (9.9) m,
with a similar change of 57.6 (10.5) m in the MPP (n
= 9) population, further supporting the selection of
2 mg/kg QW as the appropriate dosing regimen
(Additional file 3: Table S2).
Secondary outcome measures
The adult patients in MOR-005 demonstrated improve-
ments from baseline to week 120 as measured by the
3MSCT, uKS level, and the MPS HAQ domains of
self-care, caregiver assistance, and mobility (Figs. 1 and 2;
Additional file 2: Table S1). The LS mean (SE) change in
3MSCT at week 120 was 5.9 (1.7) stairs/min in the ITT
population (n = 33; P = .0010) and 6.7 (1.8) stairs/min in the
MPP population (n= 30; P= .0005) (Fig. 1b; Additional file 4:
Table 1 Patient demographics and baseline characteristics of patients ≥18 years of age in MOR-004/005 and MorCAP
ITT (n = 37) MPP (n = 32) MorCAP (n = 10)a
Demographics
Age, mean (SD), yrs 30.9 (9.7) 30.3 (8.5) 26.9 (7.8)
Male, n (%) 13 (35.1) 12 (37.5) 1 (10.0)
Ethnicity, n (%)
White 30 (81.1) 26 (81.3) 8 (80.0)
Nonwhite 7 (18.9) 6 (18.8) 2 (20.0)
Height, mean (SD), cm 114.1 (20.4) 114.6 (20.8) 106.4 (13.1)
Baseline characteristics, mean (SD)
6MWT distance, m 176.9 (67.3) 175.3 (70.7) 148.6 (109.1)
3MSCT, stairs/min 21.3 (13.1) 22.6 (13.2) 16.6 (15.3)
uKS, μg/mg 9.5 (6.2) 9.6 (6.5) 7.2 (5.0)
FVC, L 1.5 (1.1) 1.5 (1.1) 0.9 (0.3)
FEV1, L 1.2 (0.8) 1.3 (0.9) 0.7 (0.3)
MVV, L/min 43.2 (31.7) 44.9 (33.9) 29.8 (15.2)
HAQ—self-care 2.7 (2.2) 2.0 (1.9) 2.4 (1.9)
HAQ—caregiver assistance 23.0 (10.0) 23.7 (10.5) 25.8 (8.0)
HAQ—mobility 5.4 (2.7) 5.5 (2.5) 5.4 (2.4)
3MSCT 3-min stair climb test, 6MWT 6-min walk test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HAQ Health Assessment Questionnaire, ITT in-
tent to treat, MPP modified per-protocol, MVV maximal voluntary ventilation, uKS urinary keratan sulfate
an = 9 for 6MWT, 3MSCT, FVC, and FEV1; n = 7 for MVV; n = 4 for uKS. Includes only patients with data at year 2
Fig. 1 LS mean change from baseline for endurance and uKS level. LS mean change from baseline to week 120 (MOR-005) or year 2 (MorCAP)
in (a) 6MWT, (b) 3MSCT, and (c) uKS level. Error bars represent standard error. P values were calculated based on comparison of LS mean
assessments at week 120 or year 2 vs baseline. 3MSCT, 3-min stair climb test; 6MWT, 6-min walk test; ITT, intent to treat; LS, least squares; MPP,
modified per-protocol; uKS, urinary keratan sulfate
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Table S3). In MorCAP (n= 9), the 3MSCT showed no
meaningful improvement through year 2, with an LS mean
(SE) change of 4.0 (4.7) stairs/min. The uKS level decreased
in the MOR-005 study (n= 30, ITT), with an LS mean (SE)
percentage change of −65.6% (2.4%), in contrast to an
increase observed in MorCAP (n= 4) of 46.1% (58.1%)
(Fig. 1c; Additional file 4: Table S3). However, because uKS
level decreases with age, this increase is likely a result of
minor fluctuations in absolute uKS level relative to the lower
baseline uKS level (Additional file 3: Table S2). The MPS
HAQ domain score of self-care improved at week 120, with
a LS mean change (SE) of −0.43 (0.2) in the ITT population
(n= 33; P= .010) and −0.58 (0.2) in the MPP population (n
= 30; P= .001) (Fig. 2a; Additional file 4: Table S3). In the
MorCAP sample (n= 10), the self-care domain score
worsened, with LS mean change (SE) of 0.53 (0.3). On the
caregiver assistance domain score, the improvement was
−1.02 (0.9) in the MOR-005 ITT population (n= 33)
(Additional file 4: Table S3); on the mobility domain score,
the improvement was −0.76 (0.24) (Additional file 4: Table
S3). Similar results were observed in the MPP analysis
(Fig. 2b and c). Results of the MorCAP patients (n= 10) were
too variable to be conclusive on these two measures, with LS
mean (SE) changes of 0.29 (1.3) and −0.20 (0.5) on the
caregiver and mobility domain scores, respectively. No
significant changes were detected on respiratory tests for the
adult patients of either study over this time period (Fig. 3;
Supplemental Table S3).
Safety
AEs and serious AEs reported for adult patients (ITT
population) during MOR-005 were consistent with those
of the overall study population (Additional file 5: Table S4).
All adult patients experienced an AE, with the majority
being of mild to moderate severity; 73% of AEs in the adult
population were considered related to study drug. Although
most adult patients (97.3%) experienced one or more
infusion-associated reaction, only 0.4% of their infusions
were interrupted or discontinued because of an AE requir-
ing medical intervention.
Immunogenicity
Immunogenicity findings for the adult population did
not differ from those previously reported for the overall
study population [12]. Briefly, all patients treated with
elosulfase alfa developed both antidrug antibodies and
neutralizing antibodies (antibodies capable of interfering
with CI-M6PR binding in vitro; nAb). No association
was detected between higher total antidrug antibody
titer or nAb positivity and reduced efficacy measure-
ments (6MWT, 3MSCT, and uKS level) or the incidence
or severity of hypersensitivity AEs. Drug-specific im-
munoglobulin E was detected in 2 of 37 patients (5.4%);
however, positivity was not associated with the occur-
rence of anaphylaxis or other hypersensitivity AEs.
Discussion
This subanalysis of a long-term open-label study showed
that treating adults with elosulfase alfa over 120 weeks
led to improvements in 6MWT, 3MSCT, and ADL per-
formance, as well as reductions in uKS level. Although
no improvement was seen in pulmonary function, this
has been reported to decline in patients >14 years of age
[6] suggesting that treatment may still have positively
impacted disease progression. The lack of decline in the
pulmonary function of MorCAP subjects was in conflict
with the previously reported findings [6] and may be
related to the relatively small sample size.
Fig. 2 LS mean change from baseline for MPS HAQ domain scores. LS mean change from baseline to week 120 (MOR-005) or year 2 (MorCAP) in
the MPS HAQ domains of (a) self-care, (b) caregiver assistance, and (c) mobility. Error bars represent standard error. P values were calculated based
on comparison of LS mean assessments at week 120 or year 2 vs baseline. ITT, intent to treat; LS, least squares; MPP, modified per-protocol; MPS
HAQ, Mucopolysaccharidosis Health Assessment Questionnaire
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HRQOL in adults with Morquio A has been shown to be
most negatively affected in the domains of mobility, self-
care, and usual activities (eg, work, study, housework, fam-
ily, or leisure activities) and drops dramatically when pa-
tients become wheelchair bound [7]. In this report, treated
adults improved on the MPS HAQ domain scores of both
mobility and self-care, whereas MorCAP scores showed a
trend toward decline in the self-care domain (P = .07), with
no change in mobility over a similar period of time.
As has been previously noted [12], the interpretation of
results from the MOR-005 long-term study is complicated
by three main factors: the staggered transition to QW dos-
ing regimen, occurrence of orthopedic surgical procedures
during the study, and the absence of a placebo group.
Patients were transitioned from 2.0 mg/kg QOW dos-
ing to QW dosing as soon as it was identified as the op-
timal regimen, but the resulting staggered dosing
transition contributed to the complexity of the study
and precluded a meaningful analysis of QOW dosing ef-
ficacy. However, 9 adult patients from the MPP analysis
were treated at the optimal dose of 2.0 mg/kg QW
throughout the 120 weeks, and these patients improved
on 6MWT distance by 57.6 m (compared with the 34.9-
m improvement for all adults combined), a 31% increase
from the mean baseline of 186.1 m.
The exclusion of patients who underwent ortho-
pedic operations from the MPP analysis population
had the potential to bias results by removing more
severely affected patients. However, a comparison be-
tween the ITT and MPP populations at baseline
showed that the groups were similar in all measures,
including height, uKS level, and endurance (Table 1),
suggesting that there was no difference in disease
severity between the ITT and MPP groups.
In the absence of a placebo group for the extension
study, data were placed in the context of the progressive
nature of untreated Morquio A through comparison
with data from the MorCAP natural history study, with
similar inclusion and exclusion criteria applied retro-
spectively. However, the differences in baseline demo-
graphics between the studies and the small sample size
available from the natural history study limit the inter-
pretation of these comparisons.
Although the benefits of early ERT treatment for pa-
tients with Morquio A have been well established [11–13],
to our knowledge, this is the first report of long-term out-
comes of initiating ERT in adult patients with established
disease. As expected, disease symptoms at baseline ap-
peared to be more severe in the adult subgroup than in
the overall population, with a baseline 6MWT distance of
176.9 m (Table 1) vs 209.5 m for the overall MOR-004/
MOR-005 ITT population [12]. However, improvements
in multiple efficacy and HRQOL measures were observed
over the 120-weeks study of elosulfase alfa, suggesting that
adults with established disease derived benefits from ERT
initiation and treatment.
Conclusions
The patients with Morquio A in this report were adults
and, as such, had already experienced ≥18 years of mul-
tisystemic GAG accumulation and tissue damage. In this
population, ERT with elosulfase alfa led to improve-
ments in endurance, mobility, and self-care that were
sustained over 120 weeks. Analysis of similar patients
from the MorCAP natural history study suggested that
untreated adult patients do not typically experience im-
provements in these outcomes over a similar time inter-
val. The long-term improvements observed in the MPS
Fig. 3 LS mean change from baseline for respiratory tests. LS mean change from baseline to week 120 (MOR-005) or year 2 (MorCAP) in (a) FVC,
(b) FEV1, and (c) MVV. Error bars represent standard error. P values were calculated based on comparison of LS mean assessments at week 120 or
year 2 vs baseline. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ITT, intent to treat; LS, least squares; MPP, modified per-protocol;
MVV, maximal voluntary ventilation
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HAQ domain scores of self-care and mobility in particular
indicate that adult patients may experience improvements
in HRQOL with elosulfase alfa treatment. Furthermore, no
new or unexpected safety signals were identified in this
patient group. Collectively, these results support initiating
ERT in adult patients with Morquio A and are consistent
with international guidelines [11], which recommend imple-
menting elosulfase alfa ERT for all patients with a confirmed
diagnosis of Morquio A to replace deficient GALNS.
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